Phase 1/2 trial of gene therapy treatment for X-linked retinitis pigmentosa begins – Healio
|
Phase 1/2 trial of gene therapy treatment for X-linked retinitis pigmentosa begins
Healio The gene therapy, AAV-XLRPGR, uses adeno-associated virus to deliver a codon-optimized copy of the retinitis pigmentosa GTPase regulator gene into the cells of the eye, the release said. “The current trial is a multicenter open-label, dose-escalation … |
